Related Experiment Video
Updated: Mar 30, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
Abstract:
Using mouse avatars implanted with liver metastases of late-stage colorectal cancers, researchers uncovered mutations in five genes-ERBB2, EGFR, FGFR1, PDGFRA, and MAP2K1-that seem to promote cetuximab resistance. They also found that mutations in IRS2 may boost tumors' vulnerability to anti-EGFR therapy and tested specific therapies in the mice to gauge the drugs' effectiveness.
Insights
Researchers identified gene mutations (ERBB2, EGFR, FGFR1, PDGFRA, MAP2K1) causing cetuximab resistance in colorectal cancer. They also found IRS2 mutations may increase tumor sensitivity to anti-EGFR therapy.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Colorectal cancer (CRC) is a leading cause of cancer-related deaths globally.
- Acquired resistance to targeted therapies like cetuximab poses a significant clinical challenge in treating advanced CRC.
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Principles of Pharmacogenetics: Types of Genetic Variants
Pharmacogenetics of Drug Metabolism: Overview
Drug toxicity: Idiosyncratic Reactions
Pharmacogenetics and Pharmacogenomics: Overview

